Literature DB >> 17019611

The value of VEP in the diagnosis and post-operative monitoring of meningioma.

Rudy R Hidajat1, Jan L McLay, David H Goode, J Ray Hidayat.   

Abstract

Meningiomas are the most frequently reported primary intracranial neoplasms. At first they usually cause unilateral visual loss but eventually result in a bilateral loss of vision. Depending upon the size and location of the tumour, the ocular signs and symptoms of meningiomas may include visual field abnormalities, optic atrophy, papilledema, diplopia and proptosis. This case report highlights the value of visual evoked potentials (VEP) in a patient with unexplained bilateral optic atrophy and a progressive loss of vision over 2 years. As a result of a delayed response in the VEP recorded from the right eye, a compressive lesion of the optic nerve was suspected. That prompted the referring ophthalmologist to request a MRI scan which led to the diagnosis of meningioma. Following the subtotal removal of the suprasellar meningioma, the remaining vision in the right eye improved and the latency of the VEP returned to the normal range. However, the VEP from the blind eye (left) did not show any measurable response either pre- or postoperatively. Experience with this patient suggests that early recognition of optic nerve compression is vital to an optimal outcome and the VEP technique, which is much more cost-effective than MRI, is clinically useful for detecting such compressive lesions.

Entities:  

Mesh:

Year:  2006        PMID: 17019611     DOI: 10.1007/s10633-006-9025-x

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  12 in total

1.  Abnormal flash but normal pattern VEP in a cavernous sinus meningioma.

Authors:  Vikki A McBain; Graham E Holder
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

2.  Normalisation of visual evoked potentials after optic neuritis.

Authors:  Rudy R Hidajat; David H Goode
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

Review 3.  The pattern electroretinogram.

Authors:  T A Berninger; G B Arden
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

4.  Visual electrophysiology in children with tumours affecting the visual pathway. Case reports.

Authors:  J Brecelj; B Stirn-Kranjc; M Skrbec
Journal:  Doc Ophthalmol       Date:  2000-09       Impact factor: 2.379

5.  Delayed visual evoked response in optic neuritis.

Authors:  A M Halliday; W I McDonald; J Mushin
Journal:  Lancet       Date:  1972-05-06       Impact factor: 79.321

Review 6.  Epidemiology of intracranial meningioma.

Authors:  Elizabeth B Claus; Melissa L Bondy; Joellen M Schildkraut; Joseph L Wiemels; Margaret Wrensch; Peter M Black
Journal:  Neurosurgery       Date:  2005-12       Impact factor: 4.654

7.  The diagnostic yield of the evaluation for isolated unexplained optic atrophy.

Authors:  Andrew G Lee; Felix Y Chau; Karl C Golnik; Randy H Kardon; Michael Wall
Journal:  Ophthalmology       Date:  2005-05       Impact factor: 12.079

8.  Visual evoked potentials in macular disease.

Authors:  S J Bass; J Sherman; I Bodis-Wollner; S Nath
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-08       Impact factor: 4.799

Review 9.  Electrodiagnostics of chiasmal compressive lesions.

Authors:  J Brecelj
Journal:  Int J Psychophysiol       Date:  1994-05       Impact factor: 2.997

10.  Meningiomas of the anterior visual system.

Authors:  W B Wilson
Journal:  Surv Ophthalmol       Date:  1981 Nov-Dec       Impact factor: 6.048

View more
  2 in total

1.  The reproducibility of binocular pattern reversal visual evoked potentials: a single subject design.

Authors:  Tessa B Mellow; Alki Liasis; Ruth Lyons; Dorothy A Thompson
Journal:  Doc Ophthalmol       Date:  2011-03-25       Impact factor: 2.379

Review 2.  Visual electrophysiology in the clinical evaluation of optic neuritis, chiasmal tumours, achiasmia, and ocular albinism: an overview.

Authors:  Jelka Brecelj
Journal:  Doc Ophthalmol       Date:  2014-06-25       Impact factor: 2.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.